Payment overview · 2025
General Payments
$693.29
35 reported records · 12 companies
Healthcare provider profile · identity verified
Himanshu Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1962460352
Verified facts
What the public records show
CMS Open Payments records show Himanshu Patel, M.D. received $693.29 in general payments during 2025 across 35 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $240.63 | 34.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.65 | 10.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.19 | 9.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.79 | 9.5% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $64.28 | 9.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.60 | 7.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.38 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.55 | 3.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.03 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.00 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.27 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.92 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $693.29 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.00 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.40 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.65 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $65.79 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $64.28 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.60 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.60 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $44.55 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 269 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 195 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
269 | 79 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
269 | 79 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
195 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 835 | 242 |
| Omeprazole | Omeprazole | 701 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 698 | 196 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 635 | 148 |
| Metformin Hcl | Metformin Hcl | 625 | 171 |
| Simvastatin | Simvastatin | 524 | 154 |
| Losartan Potassium | Losartan Potassium | 495 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 488 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 474 | 138 |
| Lisinopril | Lisinopril | 448 | 122 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 354 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 92 |
| Gabapentin | Gabapentin | 317 | 108 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 314 | 88 |
| Diclofenac Sodium | Diclofenac Sodium | 307 | 136 |
| Famotidine | Famotidine | 296 | 89 |
| Glipizide Er | Glipizide | 280 | 76 |
| Atenolol | Atenolol | 271 | 68 |
| Jardiance | Empagliflozin | 269 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 79 |
| Azithromycin | Azithromycin | 251 | 186 |
| Furosemide | Furosemide | 235 | 75 |
| Nifedipine Er | Nifedipine | 210 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 55 |
| Ozempic | Semaglutide | 195 | 40 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 194 | 38 |
| Meloxicam | Meloxicam | 193 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 54 |
| Enalapril Maleate | Enalapril Maleate | 168 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 39 |
| Januvia | Sitagliptin Phosphate | 156 | 39 |
| Prednisone | Prednisone | 149 | 104 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 41 |
| Montelukast Sodium | Montelukast Sodium | 142 | 46 |
| Carvedilol | Carvedilol | 140 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 64 |
| Levofloxacin | Levofloxacin | 136 | 110 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 131 | 49 |
| Eliquis | Apixaban | 119 | 32 |
| Clobetasol Propionate | Clobetasol Propionate | 116 | 45 |
| Sertraline Hcl | Sertraline Hcl | 108 | 35 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 105 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 82 |
| Farxiga | Dapagliflozin Propanediol | 102 | 28 |
| Meclizine Hcl | Meclizine Hcl | 99 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 26 |
| Glipizide | Glipizide | 96 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 34 |
| Repaglinide | Repaglinide | 95 | 30 |
| Donepezil Hcl | Donepezil Hcl | 92 | 28 |
| Finasteride | Finasteride | 92 | 27 |
| Single Use Swab | Alcohol Antiseptic Pads | 92 | 45 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 91 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 88 | 27 |
| Metformin Hcl Er | Metformin Hcl | 87 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 87 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 49 |
| Glimepiride | Glimepiride | 82 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 24 |
| Mometasone Furoate | Mometasone Furoate | 75 | 28 |
| Alendronate Sodium | Alendronate Sodium | 74 | 21 |
| Xarelto | Rivaroxaban | 74 | 14 |
| Lactulose | Lactulose | 70 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 21 |
| Hydrocortisone | Hydrocortisone | 66 | 33 |
| Ramipril | Ramipril | 64 | 19 |
| Novolog Flexpen | Insulin Aspart | 63 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 61 | 23 |
| Diclofenac Sodium Er | Diclofenac Sodium | 61 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 20 |
| Entresto | Sacubitril/Valsartan | 58 | 14 |
| Fenofibrate | Fenofibrate | 58 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 55 | 28 |
| Glipizide Xl | Glipizide | 55 | 11 |
| Levetiracetam | Levetiracetam | 55 | 14 |
| Nateglinide | Nateglinide | 55 | 13 |
| Azelastine Hcl | Azelastine Hcl | 54 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 49 | 16 |
| Ibuprofen | Ibuprofen | 47 | 27 |
| Linzess | Linaclotide | 47 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 47 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | 11 |
| Ammonium Lactate | Ammonium Lactate | 45 | 11 |
| Metronidazole | Metronidazole | 45 | 36 |
| Celecoxib | Celecoxib | 42 | 22 |
| Cilostazol | Cilostazol | 42 | 12 |
| Mounjaro | Tirzepatide | 42 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 14 |
| Promethazine Hcl | Promethazine Hcl | 40 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 12 |
| Naproxen | Naproxen | 38 | 27 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 38 | 14 |
| Memantine Hcl | Memantine Hcl | 37 | 17 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 37 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 25 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 16 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 27 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | 12 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 11 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Procto-Med Hc | Hydrocortisone | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 13 |
| Tradjenta | Linagliptin | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 20 |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 22 | 17 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Permethrin | Permethrin | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | 15 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Desoximetasone | Desoximetasone | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | 13 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Terconazole | Terconazole | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $693.29 · 35 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Leqembi, MOUNJARO, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error